{"id":"W4400274003","doi":"10.1200/jco.2024.42.16_suppl.3082","title":"Final results of a first-in-human phase I dose escalation trial of daily oral zelenirstat, a n-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Spinal Cord Injury BC; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Refractory (planetary science); Maximum tolerated dose; Solid tumor; Clinical trial; Cancer research; Pharmacology; Oncology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001706136,0.0001441368,0.0007469555,0.0001947953,0.00002144609,0.000006961501,0.0000972373,0.0002914699,0.000005467662],"category_scores_gemma":[0.0006172969,0.0001149102,0.0001778752,0.0001535351,0.0001938989,0.00002654202,0.00002943136,0.0003470179,1.997378e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004460207,"about_ca_system_score_gemma":0.0006783653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001622007,"about_ca_topic_score_gemma":0.0001370662,"domain_scores_codex":[0.9967636,0.0003231991,0.002251947,0.0002559966,0.0002447854,0.000160433],"domain_scores_gemma":[0.9984049,0.0002280244,0.0009051361,0.0001396295,0.0001985468,0.0001237962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7697996,0.01630922,0.01809806,0.0003975219,0.000165239,0.0004213837,0.0005052096,0.001311006,0.07875445,0.00005754147,0.0002987261,0.113882],"study_design_scores_gemma":[0.7285821,0.1577044,0.05129718,0.001191556,0.00019767,0.0000298991,0.0001315324,0.0009245418,0.04933356,0.0003023666,0.009853257,0.0004518755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984643,0.000529766,0.0001799817,0.0001224015,0.0002325658,0.0003208309,0.00002633467,0.000002506408,0.0001213325],"genre_scores_gemma":[0.9987535,0.0001832138,0.0007642384,0.00003166486,0.0001948003,0.000004848584,0.00003488407,0.00001499096,0.00001786005],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1413952,"threshold_uncertainty_score":0.4685901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03001202910532041,"score_gpt":0.3647388429982193,"score_spread":0.3347268138928989,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}